company background image
BMY logo

Bristol-Myers Squibb NYSE:BMY Stock Report

Last Price

US$51.59

Market Cap

US$105.8b

7D

-5.1%

1Y

-23.3%

Updated

18 Mar, 2024

Data

Company Financials +

Bristol-Myers Squibb Company

NYSE:BMY Stock Report

Market Cap: US$105.8b

BMY Stock Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

BMY fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance5/6
Financial Health3/6
Dividends5/6

Narratives

Beta

Narratives bring a range of perspectives from our community.

Bristol-Myers Squibb Company Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bristol-Myers Squibb
Historical stock prices
Current Share PriceUS$51.59
52 Week HighUS$71.07
52 Week LowUS$47.58
Beta0.37
1 Month Change3.47%
3 Month Change-1.00%
1 Year Change-23.27%
3 Year Change-18.60%
5 Year Change8.63%
Change since IPO2,314.45%

Recent News & Updates

Recent updates

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Mar 07

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 07
Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative

Feb 20
We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative

Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Feb 06
Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Bristol-Myers Squibb: Massive Discount Spells Opportunity

Feb 04

BMY: Might Be Approaching A Bottom In 2024

Jan 23

Investors Aren't Entirely Convinced By Bristol-Myers Squibb Company's (NYSE:BMY) Earnings

Jan 16
Investors Aren't Entirely Convinced By Bristol-Myers Squibb Company's (NYSE:BMY) Earnings

Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also

Jan 10

Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation

Dec 31

Bristol-Myers Squibb (NYSE:BMY) Has Announced That It Will Be Increasing Its Dividend To $0.60

Dec 26
Bristol-Myers Squibb (NYSE:BMY) Has Announced That It Will Be Increasing Its Dividend To $0.60

Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now

Dec 19

Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock

Dec 12

Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.60

Dec 11
Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.60

Bristol-Myers Squibb: The Patent Expiry Challenge

Nov 23

Bristol Myers Squibb: Bright Future Ahead

Nov 17

Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Nov 08
Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Bristol-Myers Squibb: Time To Get Greedy

Oct 21

Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud

Oct 09

Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years

Sep 26

Shareholder Returns

BMYUS PharmaceuticalsUS Market
7D-5.1%-0.3%0.5%
1Y-23.3%22.4%29.0%

Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned 22.5% over the past year.

Return vs Market: BMY underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement2.8%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: BMY has not had significant price volatility in the past 3 months.

Volatility Over Time: BMY's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
188734,100Chris Boernerhttps://www.bms.com

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Bristol-Myers Squibb Company Fundamentals Summary

How do Bristol-Myers Squibb's earnings and revenue compare to its market cap?
BMY fundamental statistics
Market capUS$105.84b
Earnings (TTM)US$8.03b
Revenue (TTM)US$45.01b

13.0x

P/E Ratio

2.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BMY income statement (TTM)
RevenueUS$45.01b
Cost of RevenueUS$10.52b
Gross ProfitUS$34.49b
Other ExpensesUS$26.46b
EarningsUS$8.03b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)3.97
Gross Margin76.63%
Net Profit Margin17.83%
Debt/Equity Ratio135.1%

How did BMY perform over the long term?

See historical performance and comparison

Dividends

4.7%

Current Dividend Yield

60%

Payout Ratio

Does BMY pay a reliable dividends?

See BMY dividend history and benchmarks
When do you need to buy BMY by to receive an upcoming dividend?
Bristol-Myers Squibb dividend dates
Ex Dividend DateApr 04 2024
Dividend Pay DateMay 01 2024
Days until Ex dividend16 days
Days until Dividend pay date43 days

Does BMY pay a reliable dividends?

See BMY dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.